RLMD: Relmada Therapeutics, Inc. Stock

by  •  • Comments Off on RLMD: Relmada Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 8.99
Enterprise Value ($M) 5.13
Book Value ($M) 35.52
Book Value / Share 1.18
Price / Book 0.25
NCAV ($M) 35.50
NCAV / Share 1.18
Price / NCAV 0.25

Profitability (mra)
Return on Invested Capital (ROIC) -2.25
Return on Assets (ROA) -0.82
Return on Equity (ROE) -0.94

Liquidity (mrq)
Quick Ratio 4.45
Current Ratio 4.45

Balance Sheet (mrq) ($M)
Current Assets 45.80
Assets 45.82
Liabilities 10.30
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -83.89
Net Income -79.98
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -51.76
Cash from Investing 51.56
Cash from Financing -0.04

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Deep Track Capital, LP 2.24 -66.99
2024-03-06 13G/A Perceptive Advisors Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 1
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-28 287,867 656,678 43.84
2025-03-27 35,541 225,909 15.73
2025-03-25 318,413 904,809 35.19

(click for more detail)

Similar Companies
RGEN – Repligen Corporation RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc. RLYB – Rallybio Corporation
ROIV – Roivant Sciences Ltd.


Financial data and stock pages provided by
Fintel.io